RELAX-AHF Mortality Prediction Score Calculator
This page collects the clinical variables present in the legacy calculator. The original coefficient set and probability equation have not been verified against a reproducible published RELAX-AHF model; a mortality probability is therefore intentionally not generated.
Clinical inputs
Enter the available patient data. Use the original units shown beside each field.
Clinical context
RELAX-AHF was a randomized trial of serelaxin in selected patients hospitalized with acute heart failure. The trial assessed outcomes through 180 days, but the existence of trial mortality outcomes does not by itself establish the legacy equation on this page as a validated prediction score.
The variables retained in this form reflect those present in the supplied legacy code. They should not be interpreted as a validated model specification, and the threshold flags should not be treated as interchangeable with the continuous measurements.
How to use this page
- Use the form only to validate and organize the entered values.
- No predicted mortality percentage, score category, or treatment recommendation is calculated.
- For clinical risk assessment, use an independently validated instrument appropriate to the patient and setting.
Evidence reviewed
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomized, placebo-controlled trial.
The Lancet. 2013;381(9860):29–39.
Journal of the American College of Cardiology.
doi:10.1016/j.jacc.2012.11.005 · PMID: 23273292
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.